Subscribe
ericsphotography-istockphoto-com-us-gavel-2-1
ericsphotography / iStockphoto.com
26 March 2018Americas

Indivior pledges to appeal generic Suboxone decision

UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US judge invalidates Pernix patents in Alvogen clash
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Americas
Indivior obtains court order to block generic Suboxone
18 June 2018   Addiction treatment drug producer Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.
Americas
Indivior settles addiction drug dispute with Par
16 May 2018   Addiction drug producer Indivior has settled its patent infringement dispute with generics manufacturer Par Pharmaceutical.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Americas
US judge invalidates Pernix patents in Alvogen clash
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Americas
Indivior obtains court order to block generic Suboxone
18 June 2018   Addiction treatment drug producer Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.
Americas
Indivior settles addiction drug dispute with Par
16 May 2018   Addiction drug producer Indivior has settled its patent infringement dispute with generics manufacturer Par Pharmaceutical.

More on this story

Americas
US judge invalidates Pernix patents in Alvogen clash
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Americas
Indivior obtains court order to block generic Suboxone
18 June 2018   Addiction treatment drug producer Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.
Americas
Indivior settles addiction drug dispute with Par
16 May 2018   Addiction drug producer Indivior has settled its patent infringement dispute with generics manufacturer Par Pharmaceutical.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team